London, United Kingdom (PressExposure) September 28, 2011 -- The global hormonal contraceptive market is a fast growing market, with oral contraceptives considered to be the most common method of avoiding unplanned pregnancies. In 2010, the global contraceptives market was valued at $15.5 billion and is forecast to grow to $19.2 billion by 2017, which represents a growth rate of 3.1% from 2010 - 2017. According to a report by the Guttmacher Institute, the number of women who require publicly funded contraceptives increased by one million from 2001 - 2004. An increase in the number of women who require publicly funded contraception indicates an increasing awareness among women of contraceptive methods. The use of contraceptive devices such as condoms, intrauterine devices and vaginal rings will increase market value. Increasing awareness will accelerate growth in the contraceptive market by 2017. As a result, market growth will continue and this will attract the attention of pharmaceutical companies.
The contraceptives market has a strong pipeline base which supports growth in the market and attracts many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Teva, Watson, Bayer and Merck have active contraceptive pipelines. One of the main activities in the market at present is the development of generic versions of off-patent drugs. The entry of generic versions will strengthen the oral contraceptive market and lead to further growth in the hormonal contraceptives market. Of all pipeline molecules, 76% are in Phase II and Phase III of clinical trials. In the forecast period, the CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, will strengthen the condom market. Additionally, the entry of new companies is set to intensify competition in the condom market. Also, the presence of a highly active pipeline in this market indicates strong competition in the future.
For Sample Pages, please click or add the below link to your browser:
In the past seven years, many pharmaceutical companies have improved their product portfolios in the contraceptives market. This is primarily due to a number of prominent deals which aimed to introduce new products to the market with better efficacy and safety profiles. The acquisition of Schering AG by Bayer, Andrx by Watson and Mirecette Contraceptives by Barr Pharmaceuticals are the main acquisitions that recently took place in the contraceptives market.
GBI Research, the leading business intelligence provider, has released its latest research, "Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future" which provides insights into the global contraceptives market and market forecasts until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the most commonly used contraceptives, such as oral, topical and injectable contraceptives, intrauterine devices, condoms and vaginal rings. It also examines treatment usage patterns of oral, topical and injectable contraceptives. In addition, the report also includes insights into the contraceptives R&D product pipeline and explores the competitive landscape. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing agreements that have taken place in the global contraceptives market.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782